Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586747 | 0.78 | NNMT (0.39) | P2RX3P2RX2NNMTAPLNRSIRT6 | |
| SCHEMBL22570336 | 0.77 | NNMT (0.47) | NNMTCRHR1MTNR1AMTNR1BRAB9A | |
| SCHEMBL24455820 | 0.76 | NNMT (0.42) | P2RX3P2RX2NNMTMTNR1AMTNR1B | |
| SCHEMBL18083204 | 0.76 | NNMT (0.39) | P2RX3P2RX2NNMTMTNR1AMTNR1B | |
| SCHEMBL16800619 | 0.76 | NNMT (0.39) | NNMTMTNR1AMTNR1BTAAR1RAB9A | |
| SCHEMBL13361818 | 0.76 | RECQL (0.39) | NNMTMTNR1AMTNR1BRAB9ASIRT6 | |
| SCHEMBL22339068 | 0.75 | SLC6A2 (0.40) | P2RX3P2RX2 | |
| SCHEMBL21737273 | 0.75 | P2RX3 (0.40) | P2RX3P2RX2NNMTAPLNRSIRT6 | |
| SCHEMBL19508069 | 0.75 | P2RX3 (0.35) | P2RX3P2RX2 | |
| SCHEMBL10092223 | 0.75 | NNMT (0.49) | P2RX3P2RX2NNMTCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021136238-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | P2RX3 1300/4885P2RX2 1358/4885NNMT 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.